Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) has earned a consensus recommendation of “Hold” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $29.40.
A number of analysts have weighed in on PCRX shares. Barclays decreased their target price on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, July 1st. Royal Bank Of Canada increased their target price on Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a research report on Friday, May 1st. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Finally, Weiss Ratings raised Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, May 20th.
View Our Latest Stock Report on Pacira BioSciences
Pacira BioSciences Price Performance
Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The company had revenue of $177.38 million during the quarter, compared to the consensus estimate of $171.80 million. Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The firm’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $0.65 EPS. On average, sell-side analysts expect that Pacira BioSciences will post 1.94 earnings per share for the current fiscal year.
Insider Activity
In other news, SVP Lauren Riker sold 6,115 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the transaction, the senior vice president owned 62,284 shares of the company’s stock, valued at approximately $1,463,674. This trade represents a 8.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company’s stock.
Institutional Trading of Pacira BioSciences
A number of large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Pacira BioSciences by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock worth $677,000 after purchasing an additional 1,165 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Pacira BioSciences by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after buying an additional 367,869 shares in the last quarter. Strs Ohio bought a new stake in Pacira BioSciences during the 1st quarter worth approximately $75,000. Marshall Wace LLP bought a new position in Pacira BioSciences during the 2nd quarter valued at $4,550,000. Finally, Sei Investments Co. boosted its holdings in Pacira BioSciences by 35.3% during the second quarter. Sei Investments Co. now owns 25,357 shares of the company’s stock worth $606,000 after purchasing an additional 6,609 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.
Pacira BioSciences Company Profile
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Featured Articles
- Five stocks we like better than Pacira BioSciences
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
